Profile data is unavailable for this security.
About the company
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
- Revenue in USD (TTM)0.00
- Net income in USD-81.19m
- Incorporated2014
- Employees94.00
- LocationKorro Bio IncOne Kendall Square. Building 600-700Suite 6-401CAMBRIDGE 02139United StatesUSA
- Phone+1 (617) 468-1999
- Fax+1 (302) 636-5454
- Websitehttps://www.korrobio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organogenesis Holdings Inc | 435.47m | 5.82m | 403.02m | 862.00 | 69.92 | 1.44 | 18.98 | 0.9255 | 0.0435 | 0.0435 | 3.28 | 2.11 | 0.9628 | 4.08 | 4.63 | 505,190.30 | 1.29 | 5.46 | 1.56 | 6.90 | 75.07 | 74.94 | 1.34 | 4.81 | 2.41 | 8.78 | 0.1955 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| Alto Neuroscience Inc | 0.00 | -42.44m | 437.94m | 67.00 | -- | 2.27 | -- | -- | -1.90 | -1.90 | 0.00 | 7.18 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | -31.02 | -- | -- | -- |
| Korro Bio Inc | 0.00 | -81.19m | 448.35m | 94.00 | -- | 2.56 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 448.69m | 224.00 | -- | 0.7439 | -- | 6,598.43 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Kyverna Therapeutics Inc | 0.00 | -75.92m | 452.71m | 100.00 | -- | 1.25 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Aura Biosciences Inc | 0.00 | -78.65m | 456.79m | 88.00 | -- | 2.19 | -- | -- | -1.86 | -1.86 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -35.66 | -- | -37.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -14.53m | 457.48m | 9.00 | -- | 1.79 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 459.13m | 29.00 | -- | 5.27 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Taysha Gene Therapies Inc | 14.16m | -118.01m | 461.16m | 52.00 | -- | 7.95 | -- | 32.58 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Exscientia PLC (ADR) | 25.51m | -168.23m | 468.27m | 483.00 | -- | 1.59 | -- | 18.36 | -1.33 | -1.33 | 0.2018 | 3.41 | 0.0364 | -- | 34.98 | 52,807.47 | -24.02 | -- | -27.31 | -- | -34.40 | -- | -659.56 | -- | -- | -- | 0.0556 | -- | -26.24 | -- | -22.94 | -- | -- | -- |
| Editas Medicine Inc | 69.41m | -166.13m | 470.40m | 265.00 | -- | 1.60 | -- | 6.78 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Ocugen Inc | 7.05m | -58.50m | 470.96m | 65.00 | -- | 15.56 | -- | 66.80 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| C4 Therapeutics Inc | 20.04m | -126.07m | 472.01m | 145.00 | -- | 1.83 | -- | 23.56 | -2.37 | -2.37 | 0.3677 | 3.76 | 0.0504 | -- | 2.84 | 138,179.30 | -31.74 | -25.91 | -36.02 | -29.45 | -- | -- | -629.24 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 474.86m | 162.00 | -- | 1.39 | 312.82 | 3.99 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Northwest Biotherapeutics Inc | 1.34m | -72.21m | 475.63m | 25.00 | -- | -- | -- | 356.01 | -0.0629 | -0.0629 | 0.0012 | -0.0447 | 0.0435 | -- | -- | 53,440.00 | -228.72 | -381.58 | -- | -- | -- | -- | -5,258.91 | -6,479.25 | -- | -10.49 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
Data as of Jul 22 2024. Currency figures normalised to Korro Bio Inc's reporting currency: US Dollar USD
48.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 727.21k | 7.84% |
| Deep Track Capital LPas of 26 Apr 2024 | 714.29k | 7.70% |
| Point72 Asset Management LPas of 31 Mar 2024 | 542.66k | 5.85% |
| Eventide Asset Management LLCas of 31 Mar 2024 | 537.49k | 5.80% |
| Citadel Advisors LLCas of 31 Mar 2024 | 529.17k | 5.71% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 529.17k | 5.71% |
| Invus Public Equities Advisors LLCas of 12 Jul 2024 | 413.07k | 4.46% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 264.94k | 2.86% |
| Verition Fund Management LLCas of 31 Mar 2024 | 140.09k | 1.51% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 79.71k | 0.86% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
